Conditional risk factors in men with previous myocardial infarction: Relevance of C3 and homocysteine

Acta Cardiologica

Volumn 56, Issue 5, 2001, Pages 303-311

  Muscari, A ^a   Mele, M C ^a   Bastagli, L ^a   Poggiopollini, G ^a   Tomassetti, V ^a   Drago, G ^a   Legnani, C ^a   Barini, A ^a   Cappelletti, O ^a   Boni, P ^a   Puddu, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

C reactive protein; Complement 3; Fibrinogen; Homocysteine; Plasminogen activator inhibitor I; Previous myocardial infarction

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; COMPLEMENT COMPONENT C3; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; NITRIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; COFFEE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; FOLIC ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MALE; MULTIVARIATE ANALYSIS; RISK FACTOR;

EID: 0034800646     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.56.5.2005691     Document Type: Article

References (50)

1. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors forcoronary heart disease
2. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Executive summary
3. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial
4. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
5. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
6. Serum total homocysteine and coronary heart disease
7. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
8. The importance of triglycerides: Results from the Prospective Cardiovascular Munster (PRO-CAM) Study
9. Transient changes of serum lipoprotein(a) as an acute phase protein
10. Fibrinogen as a marker of inflammation: A clinical view
11. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - Evidence that the liver contributes to acute phase behaviour of PAI-1
12. Interleukin-6 stimulates hepatic triglyceride secretion in rats
13. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
14. Risk factors for coronary heart disease and acute-phase proteins. A population-based study
15. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study
16. Relationship between serum C3 levels and traditional risk factors for myocardial infarction
17. Relation of serum C3 to fasting insulin, risk factors and previous ischemic events in middle-aged men
18. Gerinnungphysiologische schnellmethode zur bestimmung des fibrinogens
19. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma
20. Quantitative studies of the secretion of complement component C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and Lysosomal enzyme release
21. Adipsin and an endogenous pathway of complement from adipose cells
22. Human C'3: Evidence for the liver as the primary site of synthesis
23. The acute phase response
24. Association of serum C3 levels with the risk of myocardial infarction
25. Insulin resistance and compensatory hyperinsulinemia: Role in hypertension, dyslipidemia, and coronary heart disease
26. Serum complement protein C3 is a marker of insulin resistance, which is related to obesity, but not to hyperglycemia
27. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration
28. Serum complement and familial combined hyperlipidemia
29. Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation stimulating protein
30. Coordinate regulation of triacyglycerol synthesis and glucose transport by acylation-stimulating protein
31. The complement system has associations also with glucose metabolism
32. Leukocyte activation in atherosclerosis: Correlation with risk factors
33. Relationship of serum C3 complement with insulin resistance and coronary heart disease - Cause, consequence or common antecedent?
34. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha
35. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes
36. Long-term effects of pravastatin on plasma concentration of C-reactive protein
37. Inhibition of proinflammatory cytokine production by pravastatin
38. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes
39. Folic acid - An innocuous means to reduce plasma homocysteine
40. Plasma homocysteine as a cardiovascular risk factor: Causal, consequential, or of no consequence?
41. The effects of alcohol on coagulation and fibrinolytic factors: A controlled trial
42. Plasma triglycerides and lipoprotein(a): Inverse relationship in a hyperlipidemic Italian population
43. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response
44. Determinants of lipoprotein(a) levels in a middle-aged working population
45. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations
46. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men
47. Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents
48. Plasma total homocysteine levels in subjects with hyperinsulinemia
49. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose
50. Adjusting for multiple testing - When and how?